Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00951483 · ClinicalTrials.gov registry record · Phase 4
Cardiovascular Biomarkers and Quetiapine in Depression and Anxiety Patients
A Phase 4 study, sponsored by Loyola University.
- Completed
- Registry status
- Phase 4
- Development phase
- 91
- Enrollment target
NCT00951483 is a Phase 4 study that has completed, run by Loyola University. The registered enrollment target is 91 participants.
The verdict
NCT00951483, a Phase 4 study, has completed, sponsored by Loyola University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 91 participants
- Enrollment target
Study Summary
No suitable treatment has been identified to reverse and ideally prevent, the cardiovascular disease risk associated with depression and anxiety. The purpose of this study is to determine if quetiapine treatment of depression can reverse the signs of arterial stiffening that often occurs in depression and anxiety, and which are believed to be risk factors for future heart disease.
Interventions
- DRUG Quetiapine-XR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 91 participants |
| Start Date | 2009-07 |
| Est. Completion | 2011-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00951483
The ClinicalTrials.gov registry entry for NCT00951483 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 91 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Loyola University, which has 92 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Quetiapine-XR is the first listed.
NCT00951483 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00951483 about?
NCT00951483 is a clinical study titled "Cardiovascular Biomarkers and Quetiapine in Depression and Anxiety Patients". No suitable treatment has been identified to reverse and ideally prevent, the cardiovascular disease risk associated with depression and anxiety. The purpose of this study is to determine if quetiapine treatment of depression can reverse the signs of arterial stiffening that often occurs in depressi...
What is the current status of trial NCT00951483?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 91 participants. The study started on 2009-07. Estimated completion is 2011-10.
What interventions are being tested in trial NCT00951483?
The interventions under investigation include: Quetiapine-XR (DRUG).
Who is sponsoring clinical trial NCT00951483?
This trial is sponsored by Loyola University, which has 92 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.